
Merck halted late-stage trials of its experimental blood cancer drug nemtabrutinib on Tuesday after a safety review. The independent monitoring committee found the treatment's risks outweigh its potential benefits. The decision terminates a broad clinical program targeting chronic lymphocytic leukemia.








